MONTREAL, Sept. 18 /CNW Telbec/ - Haemacure Corporation (TSX: HAE)
announced today that Joseph Galli, Chairman and Chief Executive Officer of
Haemacure, will present at the Sachs 8th Annual Biotech in Europe Investor
Forum, being held September 23-24 in Zurich, Switzerland. Mr. Galli will
present a corporate progress report, including an update on the Company's lead
product candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation
is scheduled to begin at 12:10 p.m. local time on Tuesday, September 23rd.
Information on the Forum is available at
http://www.sachsforum.com/zurich08/index.html.
